Across TCGA pan-cancer cohorts, NRARP Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NRARP data layer compared with 26 for mass-spec protein.
The strongest signal is observed in cholangiocarcinoma (CHOL), where higher NRARP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NRARP expression acts as an unfavorable survival marker.
CHOL are the cancer types where NRARP Mutation most reproducibly stratifies survival.